Argobio's goal is to create and launch at least five ambitious biotechnology companies over the next five years. The incubator will focus on selected therapeutic areas including neurological disorders, rare diseases, oncology and immunology. The investors will have the unique opportunity to partecipate in the biotech companies created by Argobio.

Argobio, which is backed by €50 million in committed capital, was founded by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Besides Angelini Pharma, the other complementary strategic investors are Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.

In 2020, Angelini Pharma created a new Corporate Venturing unit with the objective of investing in innovative startups and Venture Capital companies operating in the life sciences sector and active in strategic therapeutic areas for the company (central nervous system and rare diseases).

Argobio is the first of several investments that Angelini Pharma commits to make with the aim of creating innovative startups.